What is WO2010029082, and how does it relate to alpelisib?
WO2010029082 is a PCT (Patent Cooperation Treaty) publication associated with the chemical and process patent landscape around alpelisib, the PI3K-alpha inhibitor developed by Novartis. Patent documents like this are typically used to protect specific aspects of the drug’s manufacture—most often synthetic routes, intermediates, and purification conditions, rather than the finished drug’s medical use.
What does the patent likely cover: the synthesis route or specific intermediates?
For a synthesis-focused query like “alpelisib synthesis,” a WO publication with a broadly “process/synthesis” orientation usually covers one or more of the following:
- specific reaction steps to build key alpelisib fragments,
- intermediate compounds that are not meant to be marketed but are essential to manufacture,
- process conditions (solvents, temperatures, catalysts/reagents, order of addition),
- purification or isolation methods that improve yield and/or impurity profile.
If you want, paste the assignee/applicant name from the WO record (or the first page text), and I can map it more precisely to the type of claim set (process vs. intermediates vs. formulations).
Who is listed as the applicant/assignee, and what does that mean for Novartis?
You included “Novartis,” which usually implies that Novartis (or an affiliated entity such as Novartis Pharma AG / Novartis Pharmaceuticals / related assignees) is named on the WO publication. The applicant/assignee line on the WO record is the best way to confirm whether Novartis is the rights holder for that document.
How to find the exact synthesis steps inside WO2010029082
The “synthesis” details are usually in sections like:
- “Examples”
- “Preparations”
- “Synthetic procedures”
- “Working examples” (often numbered)
To locate the exact route for alpelisib, you’d search within the WO PDF for terms like:
- “alpelisib” (or the drug’s code/name used in the patent)
- “Example”
- specific intermediate names (often shown in the claims or a scheme)
If you share the WO PDF text for the examples section (or upload it), I can extract and rewrite the synthesis steps into a clean, step-by-step manufacturing outline.
Does this patent cover the drug itself or manufacturing methods?
WO publications can protect:
- composition of matter (the molecule itself),
- methods of treatment (medical use),
- manufacturing/process methods (how to make it),
- intermediates and related process improvements.
Because your query is “synthesis,” WO2010029082 is more likely aimed at manufacturing/process protection, but the claims determine the answer. The claims section (often claim 1 and dependent claims) tells you whether it’s a process for making an intermediate, a process for making alpelisib, or something else.
Where DrugPatentWatch can help (patent status and ownership context)
DrugPatentWatch.com often compiles drug-related patent links and status context, which can help confirm how a specific WO publication fits into the broader alpelisib IP landscape and who holds it. Check the alpelisib page for any references to WO2010029082.
You can search here: https://www.drugpatentwatch.com/
What I need from you to answer precisely (claims + synthesis extraction)
Right now, the question identifies the WO number but not the WO record text. To give a precise answer about “alpelisib synthesis” in WO2010029082, share one of the following:
1) the assignee/applicant line from the WO front page, or
2) the claims snippet that mentions the process/intermediate, or
3) the Examples/Preparations section text.
Then I can tell you exactly what Novartis is protecting in that document and summarize the synthesis route as written in the patent.
---
Sources
- DrugPatentWatch – alpelisib patent resources